| Literature DB >> 29362666 |
Yiran Sun1,2, Qiuxia Lu1,2, Libo He1,2, Yueyue Shu1,2, Shiyan Zhang1,2, Shancai Tan1,2, Lin Tang1,2.
Abstract
Excessive amounts of reactive oxygen species (ROS) in the body are a key factor in the development of hepatopathies such as hepatitis. The aim of this study was to assess the antioxidation effect in vitro and hepatoprotective activity of the active fragment of Veronica ciliata Fisch. (VCAF). Antioxidant assays (DPPH, superoxide, and hydroxyl radicals scavenging) were conducted, and hepatoprotective effects through the application of tert-butyl hydroperoxide- (t-BHP-) induced oxidative stress injury in HepG2 cells were evaluated. VCAF had high phenolic and flavonoid contents and strong antioxidant activity. From the perspective of hepatoprotection, VCAF exhibited a significant protective effect on t-BHP-induced HepG2 cell injury, as indicated by reductions in cytotoxicity and the levels of ROS, 8-hydroxydeoxyguanosine (8-OHdG), and protein carbonyls. Further study demonstrated that VCAF attenuated the apoptosis of t-BHP-treated HepG2 cells by suppressing the activation of caspase-3 and caspase-8. Moreover, it significantly decreased the levels of ALT and AST, increased the activities of acetyl cholinesterase (AChE), glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT), and increased total antioxidative capability (T-AOC). Collectively, we concluded that VCAF may be a considerable candidate for protecting against liver injury owing to its excellent antioxidant and antiapoptosis properties.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29362666 PMCID: PMC5736906 DOI: 10.1155/2017/4727151
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1Effects of the antioxidant activity of the VCAF: (a) DPPH radical, (b) superoxide anion radical, and (c) hydroxyl radical. Data are presented as means ± SD (n = 3). VCAF: active fragment of V. ciliata Fisch.; VC: vitamin C.
Antioxidant activity of VCAF (IC50, μg/mL).
| Sample | IC50( | ||
|---|---|---|---|
| DPPH | Superoxide anion | Hydroxyl | |
| VCAF | 6.882 ± 0.83 | 20.838 ± 1.319 | 5.021 ± 0.701 |
| VC | 3.919 ± 0.593 | 9.674 ± 0.986 | 3.620 ± 0.559 |
Figure 2Cytotoxicity and the cytoprotective effects of VCAF. The viability of HL-7702 cells and HepG2 cells was performed by a CCK-8 assay. (a) HL-7702 cells were treated with VCAF in different concentrations (20–200 μg/mL) for 24 and 48 hours. (b) HepG2 cells were pretreated for 2 h with the indicated concentrations of VCAF and then incubated for 2 h with t-BHP (5 mM). ##p < 0.01 versus control; ∗∗p < 0.01 versus 5 mM t-BHP.
Figure 3The effects of VCAF on oxidative stress injury. (a) Intracellular ROS levels. (b) Intracellular 8-OHdG concentrations. (c) Intracellular protein carbonyls content. ##p < 0.01 versus control; ∗p < 0.01 and ∗∗p < 0.01 versus 5 mM t-BHP.
Figure 4The protective effects of VCAF on apoptosis. (a) Fluorescence images (DAPI staining) of HepG2 cells at magnification of 40x. (b) Apoptosis of HepG2 cells stained with Annexin V-FITC/PI was quantified by flow cytometric analysis. (c) Analysis of the activation of caspase-3, caspase-8, and caspase-9 in the total cell lysates of HepG2 cells. ##p < 0.01 versus control; ∗∗p < 0.01 versus 5 mM t-BHP.
Figure 5The effects of VCAF on AST, ALT, and AChE activities. (a) AST and ALT activities of cellular supernatant. (b) Intracellular AChE activities. ##p < 0.01 versus control; ∗∗p < 0.01 versus 5 mM t-BHP.
Figure 6The effects of VCAF on antioxidase activities. (a) SOD activity in the supernatants of HepG2 cell lysates. (b) GSH activity in the supernatants of HepG2 cell lysates. (c) CAT activity in the supernatants of HepG2 cell lysates. (d) T-AOC in the supernatants of HepG2 cell lysates. ##p < 0.01 versus control; ∗∗p < 0.01 versus 5 mM t-BHP.
Figure 7UPLC chromatograms of VCAF detected at 260 nm.